BioCentury
ARTICLE | Clinical News

Fluidosomes Tobramycin: Phase IIa started

September 8, 2008 7:00 AM UTC

Axentis began an international Phase IIa trial to evaluate 2 dosages of ARB-CF0223 in 24 patients with CF. The company licensed the product, which has European Orphan designation for the indication, f...